Elite in Brain Tumor

Dr. Rohit K. Jain

Oncology | Hematology Oncology | Hematology
New York Queens Medicine And Surgery, P.C.
5645 Main St, 
Flushing, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Elite in Brain Tumor
New York Queens Medicine And Surgery, P.C.
5645 Main St, 
Flushing, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rohit Jain is an Oncologist and a Hematologist Oncology provider in Flushing, New York. Dr. Jain is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Penectomy, and Endoscopy. Dr. Jain is currently accepting new patients.

His clinical research consists of co-authoring 275 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
New York-Presbyterian Hospital
New York-Presbyterian/queens
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

NEW YORK QUEENS MEDICINE AND SURGERY, P.C.
5645 Main St, Flushing, NY 11355
Other Locations
WEILL MEDICAL COLLEGE OF CORNELL
1305 York Ave, Suite 12, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Abiraterone Acetate
Study Phase: Early Phase 1
A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
A Phase 1 Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With Muscle Invasive Bladder Cancer (MIBC)
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drugs: CG0070, Nivolumab
Study Phase: Phase 1
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
A Phase 1/1b Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: SRF388
Study Phase: Phase 1
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Phase I/II Study of Ipilimumab Plus Nivolumab (IPI-NIVO) Combined With Sacituzumab Govitecan (SG)as First-line Treatment for Cisplatin-ineligible Metastatic Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab, Sacituzumab govitecan
Study Phase: Phase 1/Phase 2
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
A Window-of-opportunity Trial of Abemaciclib Followed by Radical Cystectomy in Patients With Platinum-ineligible Urothelial Carcinoma to Evaluate CDK4/6-dependent Phosphorylation of Pocket Proteins and Clonal Evolution Dynamics
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Early Phase 1
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Lirilumab
Study Phase: Phase 1
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment Status: Completed
Publish Date: July 26, 2024
Intervention Type: Procedure, Other, Biological, Drug
Study Drugs: Atezolizumab, Glycosylated Recombinant IL-7
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Biological
Study Drugs: CV-301, Atezolizumab
Study Phase: Phase 2
View 9 Less Clinical Trials

275 Total Publications

Beyond the brain: The colorectal impact of Parkinson's disease.
Beyond the brain: The colorectal impact of Parkinson's disease.
Journal: Journal of Parkinson's disease
Published: September 24, 2025
Similar Doctors
Elite in Brain Tumor
Dr. Ingo K. Mellinghoff
Oncology
Elite in Brain Tumor
Dr. Ingo K. Mellinghoff
Oncology

Memorial Neurology Group

1275 York Ave, 
New York, NY 
 (6.9 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ingo Mellinghoff is an Oncologist in New York, New York. Dr. Mellinghoff is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Gliomatosis Cerebri.

Elite in Brain Tumor
Dr. Howard A. Fine
Oncology | Neurology
Elite in Brain Tumor
Dr. Howard A. Fine
Oncology | Neurology

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (6.8 miles away)
212-746-2323
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Howard Fine is an Oncologist and a Neurologist in New York, New York. Dr. Fine is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Distinguished in Brain Tumor
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology
Distinguished in Brain Tumor
Dr. Lyndon J. Kim
Neurosurgery | Oncology | Hematology Oncology

Icahn School Of Medicine At Mount Sinai

1 Gustave Levy Place, Mount Sinai Emergency Room, 
New York, NY 
 (7.3 miles away)
212-241-4572
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lyndon Kim is a Neurosurgery specialist and an Oncologist in New York, New York. Dr. Kim is rated as an Elite provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 8 Advanced Conditions
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile